Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients?

NCT04654429 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 628

Last updated 2021-10-14

No results posted yet for this study

Summary

This study will look at the incidence of post-spinal shivering (PSS) among the obstetrics population and will investigate whether higher operation theater (OT) temperature range or/and IV Ondansetron are able to reduce the incidence of PSS. This is a double-blind, randomized, factorial study, patients will be grouped into 4 groups - LP, HP, LO, HO (L= low-temperature range, H= high-temperature range, P= placebo, O=Ondansetron). All patients undergoing cesarean section under spinal anesthesia will be recruited, and it will be conducted in obstetrics OT.

Conditions

  • Temperature Change, Body
  • Chills
  • Tremor
  • Nausea, Postoperative
  • Vomiting, Postoperative
  • Postoperative Shivering

Interventions

DRUG

IV Ondansetron 4mg

IV ondansetron 4mg

OTHER

Higher OT temperature range

OT temperature set to 19-22 degree celsius

DRUG

Placebo

IV Normal Saline 2cc will be given

OTHER

Lower OT temperature Range

OT temperature set to 17-19 degree celsius

Sponsors & Collaborators

  • Dr Lim Siu Min

    lead OTHER

Principal Investigators

  • SIU MIN LIM, L · MALAYA UNIVERSITY

  • SOOK HUI CHAW, AP · MALAYA UNIVERSITY

  • CAROLYN YIM CHUE WAI, AP · MALAYA UNIVERSITY

  • JAUHARATUNNUR ISHAK, M · MALAYA UNIVERSITY

  • TSYR XIANG TEOH, M · MALAYA UNIVERSITY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04654429 on ClinicalTrials.gov